Elysium Therapeutics: Valuation, Funding & Investors
Elysium Therapeutics is an emerging biopharmaceutical company developing treatments to prevent and reverse overdoses caused by highly potent synthetic opioids, with a specific focus on oral fentanyl and nitazenes. The company is advancing SOOPR™, a rapid-onset, long-acting naloxone prodrug rescue therapy, and developing SMART™ and O2P™ product approaches to improve opioid safety and reduce overdose fatalities.
Leadership & Board
- Current Number of Employees
- 4
- Current LinkedIn Followers
- 289
Latest Estimated Valuation
- Total Amount Raised
- $8M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $8M
- Latest Funding Round
- Convertible Notes
Employee Trend
Elysium Therapeutics had 4 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Elysium Therapeutics had 289 followers as of November 16, 2026. The number of followers increased by 0 (0.00%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 28, 2026 | Convertible Notes | $7.50M | ― |
Similar Companies
A snapshot of private companies similar to Elysium Therapeutics, helping you discover and navigate related company profiles.









